An estimated 90% of patients treated with radiotherapy for breast cancer will develop radiation-induced dermatitis. On the molecular level, radiation upregulates cytokine cascades and fibro-inflammatory pathways, leading to substantial fibrosis, the hallmark of chronic RT damage.

As complexity of radiation therapy increases, ensuring that health care institutions meet rigorous quality standards becomes paramount.

The role of radiotherapy in the management of benign diseases is ever expanding. Non-malignant entities of the head and neck are particularly complex and represent therapeutic challenges given the potential for treatment-associated morbidities.

The management of patients with nasal cavity and paranasal sinus tumors is challenging and constantly evolving. It often requires true trimodality care involving radiation oncology, otolaryngology and medical oncology, along with a variety of different supportive services.

This activity discusses current evidence for radiotherapy in the management of SCLC. New phase III data combining radiation and immunotherapy (Adriatic, LU-005) is presented, with particular attention on the importance of timing of immunotherapy relative to chemoradiation.

Cancer treatment guidelines are drafted to ensure appropriate use of existing evidence and promote safe practice. While guidelines strive to keep pace with research and new technology, they often don’t address the ground level situation in community practice especially for LMIC.

While best known for its use in cancer, radiotherapy (RT) can be used as a successful treatment for several nonmalignant diseases. Nonetheless, the use of non-oncological RT is uncommon, and its utilization varies from country to country.

There are many ongoing advances in the management of high risk and locally advanced prostate cancer, including concepts of systemic therapy intensification and de-escalation, dose escalation, and the use of biomarkers.